Cigna (CGN) AI Stock Analysis

Cigna

(XETRA:CGN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified growth platformsCigna combines insurance with pharmacy, specialty, behavioral health, and care-management services, creating multiple recurring revenue streams. Recent growth across both major platforms indicates broad demand and reduces reliance on a single product or customer segment over the coming quarters.

Negative Factors

Medical cost pressureSustained high medical-cost inflation can compress insurance margins when claims rise faster than premiums or pricing resets. Although guidance was maintained, continued pressure raises the risk that elevated utilization and provider costs reduce earnings durability across future reporting periods.

Cigna (CGN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 78.80B
Dividend Yield: 1.98%
Average Volume (3M): 31
Price to Earnings (P/E): 12.3
Beta (1Y): 0.12
Revenue Growth: 0.80%
EPS Growth: 22.54%
Country: Germany
Employees: 66,685
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Plans

Cigna Business Overview & Revenue Model

Company Description

Cigna Group, established in 1792 and headquartered in Bloomfield, Connecticut, provides insurance products and related services across the United States. The company operates through two primary segments. Its Evernorth division offers a comprehensive...

Cigna Earnings Call Summary

Earnings Call Date:Jul 29, 2026(Q2-2026)|% Change Since:0.66%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call conveyed strong operational and financial momentum driven by specialty drug growth, Evernorth and Cigna Healthcare outperformance, AI-enabled clinical initiatives with measurable outcomes, solid revenue and EPS beats, and an upgraded full-year EPS outlook. Offsetting items include PBS earnings pressure from transition investments and economic shifts due to biosimilars, moderating GLP-1 utilization, persistently elevated medical cost trends, IDR-related affordability concerns, and one-time special charges. Overall, the positive drivers (revenue growth, margin gains in Specialty, upgraded guidance, retention/new-business strength, AI initiatives) materially outweigh the manageable challenges described.

Positive Updates

Strong Q2 Financial Results

Total revenues of $71.7 billion and adjusted earnings per share of $7.78 in Q2; adjusted after-tax earnings of $2.1 billion for the quarter. Company delivered results ahead of expectations across the enterprise.

Negative Updates

Pharmacy Benefit Services Earnings Pressure and Transition Investment

Pretax adjusted earnings for Pharmacy Benefit Services were $609 million, down from prior year. Results were impacted by renewals/extensions of large client contracts and investments for transition to the rebate-free 'Signature' model; transition expenses will continue at similar levels in 2027 before ramping down later.

Company Guidance

Cigna raised its full‑year 2026 adjusted EPS outlook to at least $30.45 (Q2 adjusted EPS $7.78; Q2 adjusted after‑tax earnings $2.1B) on total Q2 revenues of $71.7B; segment guidance includes Evernorth full‑year pretax adjusted earnings of at least $6.9B (Q2 Evernorth revenues $61.5B; Q2 pretax adj earnings $1.7B; Specialty & Care Q2 pretax adj earnings $1.1B, +22% y/y; PBS Q2 pretax adj earnings $609M) and Cigna Healthcare full‑year pretax adjusted earnings of at least $4.55B (Q2 revenues $11.8B; Q2 pretax adj earnings $1.3B). Management reiterated full‑year medical care ratio guidance (Q2 MCR 84.5%) and expects Q3 MCR slightly above Q2, second‑half adjusted EPS to be split roughly evenly between Q3 and Q4, and Cigna Healthcare’s Q3 pretax adjusted earnings to be over 60% of second‑half earnings. Capital/cash metrics: Q2 operating cash flow in line with expectations, full‑year operating free cash flow ~ $9B (back‑half weighted), debt‑to‑capitalization 42.8% at June 30 (targeting ~40% year‑end), repurchased ~900k shares for ~$250M in Q2; Q2 after‑tax special items were $153M ($0.58/sh).

Cigna Risk Analysis

Cigna disclosed 27 risk factors in its most recent earnings report. Cigna reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Cigna Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:CGN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELV	69Neutral	$90.76B	17.89	11.59%	1.64%	3.60%	-4.06%
CNC	64Neutral	$33.89B	23.13	6.78%	―	9.71%	―
UNH	62Neutral	$365.29B	23.23	16.10%	2.23%	3.33%	―
HUM	60Neutral	$49.77B	38.92	6.91%	0.85%	18.33%	-18.53%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CVS	48Neutral	$115.43B	23.56	6.43%	2.95%	7.41%	6.51%

* Healthcare Sector Average

Performance Comparison

DE:CGN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:CGN	Cigna	268.10	61.79	29.95%
CNC	Centene	68.45	33.95	98.41%
CVS	CVS Health Corp	90.25	14.15	18.59%
HUM	Humana	414.50	138.19	50.01%
UNH	Unitedhealth Group Inc.	406.97	81.84	25.17%
ELV	Elevance Health, Inc.	420.07	112.99	36.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cigna AI Stock Analysis